Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers

Alessandro Rolfo, Rossella Attini, Anna M. Nuzzo, Annalisa Piazzese, Silvia Parisi, Martina Ferraresi, Tullia Todros, Giorgina B. Piccoli

Research output: Contribution to journalArticle

Abstract

Preeclampsia, affecting 5-8% of pregnancies, is the main cause of fetal-maternal mortality and morbidity. The differential diagnosis with chronic kidney disease (CKD) is a challenge owing to the overlapping clinical features. No biomarker has been found to discriminate between the two conditions. Here, we tested whether maternal serum levels of placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1), markers of preeclampsia, could be used to discriminate between 34 patients with preeclampsia, 23 patients with CKD during pregnancy, and 38 healthy pregnant women. Serum levels of PlGF and sFlt-1 were determined during the third trimester by commercially available immunoassays. In preeclampsia, sFlt-1 levels were significantly increased in comparison with that in CKD and in the control women. Serum levels of PlGF in preeclampsia were significantly decreased relative to both controls and patients with CKD. The sFlt-1 to PlGF ratio was significantly increased in preeclampsia (median 436) compared with controls (median 9.4) and CKD (median 4.0). No differences were found between controls and patients with CKD. Thus, our study suggests that it is possible to discriminate between preeclampsia and CKD during pregnancy by determining maternal serum levels of sFlt-1 and PlGF and their ratio.

Original languageEnglish
Pages (from-to)177-181
Number of pages5
JournalKidney International
Volume83
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Pre-Eclampsia
Chronic Renal Insufficiency
Biomarkers
Protein-Tyrosine Kinases
Intercellular Signaling Peptides and Proteins
Serum
Pregnancy
Mothers
Fetal Mortality
Maternal Mortality
Third Pregnancy Trimester
Immunoassay
Pregnant Women
Differential Diagnosis
Morbidity

Keywords

  • chronic kidney disease
  • endothelium
  • glomerulopathy
  • hypertension

ASJC Scopus subject areas

  • Nephrology

Cite this

Rolfo, A., Attini, R., Nuzzo, A. M., Piazzese, A., Parisi, S., Ferraresi, M., ... Piccoli, G. B. (2013). Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney International, 83(1), 177-181. https://doi.org/10.1038/ki.2012.348

Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. / Rolfo, Alessandro; Attini, Rossella; Nuzzo, Anna M.; Piazzese, Annalisa; Parisi, Silvia; Ferraresi, Martina; Todros, Tullia; Piccoli, Giorgina B.

In: Kidney International, Vol. 83, No. 1, 01.2013, p. 177-181.

Research output: Contribution to journalArticle

Rolfo, A, Attini, R, Nuzzo, AM, Piazzese, A, Parisi, S, Ferraresi, M, Todros, T & Piccoli, GB 2013, 'Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers', Kidney International, vol. 83, no. 1, pp. 177-181. https://doi.org/10.1038/ki.2012.348
Rolfo, Alessandro ; Attini, Rossella ; Nuzzo, Anna M. ; Piazzese, Annalisa ; Parisi, Silvia ; Ferraresi, Martina ; Todros, Tullia ; Piccoli, Giorgina B. / Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. In: Kidney International. 2013 ; Vol. 83, No. 1. pp. 177-181.
@article{8e8f6d33eb984bbc833bbff21696663e,
title = "Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers",
abstract = "Preeclampsia, affecting 5-8{\%} of pregnancies, is the main cause of fetal-maternal mortality and morbidity. The differential diagnosis with chronic kidney disease (CKD) is a challenge owing to the overlapping clinical features. No biomarker has been found to discriminate between the two conditions. Here, we tested whether maternal serum levels of placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1), markers of preeclampsia, could be used to discriminate between 34 patients with preeclampsia, 23 patients with CKD during pregnancy, and 38 healthy pregnant women. Serum levels of PlGF and sFlt-1 were determined during the third trimester by commercially available immunoassays. In preeclampsia, sFlt-1 levels were significantly increased in comparison with that in CKD and in the control women. Serum levels of PlGF in preeclampsia were significantly decreased relative to both controls and patients with CKD. The sFlt-1 to PlGF ratio was significantly increased in preeclampsia (median 436) compared with controls (median 9.4) and CKD (median 4.0). No differences were found between controls and patients with CKD. Thus, our study suggests that it is possible to discriminate between preeclampsia and CKD during pregnancy by determining maternal serum levels of sFlt-1 and PlGF and their ratio.",
keywords = "chronic kidney disease, endothelium, glomerulopathy, hypertension",
author = "Alessandro Rolfo and Rossella Attini and Nuzzo, {Anna M.} and Annalisa Piazzese and Silvia Parisi and Martina Ferraresi and Tullia Todros and Piccoli, {Giorgina B.}",
year = "2013",
month = "1",
doi = "10.1038/ki.2012.348",
language = "English",
volume = "83",
pages = "177--181",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers

AU - Rolfo, Alessandro

AU - Attini, Rossella

AU - Nuzzo, Anna M.

AU - Piazzese, Annalisa

AU - Parisi, Silvia

AU - Ferraresi, Martina

AU - Todros, Tullia

AU - Piccoli, Giorgina B.

PY - 2013/1

Y1 - 2013/1

N2 - Preeclampsia, affecting 5-8% of pregnancies, is the main cause of fetal-maternal mortality and morbidity. The differential diagnosis with chronic kidney disease (CKD) is a challenge owing to the overlapping clinical features. No biomarker has been found to discriminate between the two conditions. Here, we tested whether maternal serum levels of placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1), markers of preeclampsia, could be used to discriminate between 34 patients with preeclampsia, 23 patients with CKD during pregnancy, and 38 healthy pregnant women. Serum levels of PlGF and sFlt-1 were determined during the third trimester by commercially available immunoassays. In preeclampsia, sFlt-1 levels were significantly increased in comparison with that in CKD and in the control women. Serum levels of PlGF in preeclampsia were significantly decreased relative to both controls and patients with CKD. The sFlt-1 to PlGF ratio was significantly increased in preeclampsia (median 436) compared with controls (median 9.4) and CKD (median 4.0). No differences were found between controls and patients with CKD. Thus, our study suggests that it is possible to discriminate between preeclampsia and CKD during pregnancy by determining maternal serum levels of sFlt-1 and PlGF and their ratio.

AB - Preeclampsia, affecting 5-8% of pregnancies, is the main cause of fetal-maternal mortality and morbidity. The differential diagnosis with chronic kidney disease (CKD) is a challenge owing to the overlapping clinical features. No biomarker has been found to discriminate between the two conditions. Here, we tested whether maternal serum levels of placental growth factor (PlGF) and soluble FMS-like tyrosine kinase-1 (sFlt-1), markers of preeclampsia, could be used to discriminate between 34 patients with preeclampsia, 23 patients with CKD during pregnancy, and 38 healthy pregnant women. Serum levels of PlGF and sFlt-1 were determined during the third trimester by commercially available immunoassays. In preeclampsia, sFlt-1 levels were significantly increased in comparison with that in CKD and in the control women. Serum levels of PlGF in preeclampsia were significantly decreased relative to both controls and patients with CKD. The sFlt-1 to PlGF ratio was significantly increased in preeclampsia (median 436) compared with controls (median 9.4) and CKD (median 4.0). No differences were found between controls and patients with CKD. Thus, our study suggests that it is possible to discriminate between preeclampsia and CKD during pregnancy by determining maternal serum levels of sFlt-1 and PlGF and their ratio.

KW - chronic kidney disease

KW - endothelium

KW - glomerulopathy

KW - hypertension

UR - http://www.scopus.com/inward/record.url?scp=84871753612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871753612&partnerID=8YFLogxK

U2 - 10.1038/ki.2012.348

DO - 10.1038/ki.2012.348

M3 - Article

C2 - 23014459

AN - SCOPUS:84871753612

VL - 83

SP - 177

EP - 181

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -